Mesoblast Stem Cell Therapy Study shows 83% Survival in patients on Ventilators from COVID-19
News was announced today from Biospace that patients with ARDS (Acute Respiratory Distress) demonstrated an 83% survival after 2 IV infusions of Mesoblast’s product Ryoncil (remestemcel-L). This med is NOT FDA approved for treating COVID-19 according to BioSpace. In the study, 9/12 patients came off ventilators within 10 days, with 7 patients discharged from the hospital. […]